FRANKFURT (Reuters) – Germany’s Fresenius Medical Care, said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral effect on how many patients will require the company’s kidney dialysis services in the future.
The company’s shares, and those of its closest rival DaVita, plunged on Wednesday after Novo Nordisk’s Ozempic showed early success in a trial to treat kidney failure in diabetes patients.
(Reporting by Ludwig Burger. Editing by Jane Merriman)
